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MetabolismDiabetes mellitus is a serious disease affecting about 5% of people worldwide. Diabetes is characterized by
hyperglycemia and impairment in insulin secretion and/or action. Moreover, diabetes is associatedwithmetabolic
abnormalities and serious complications. Resveratrol is a natural, biologically active polyphenol present indifferent
plant species and known to have numerous health-promoting effects in both animals and humans. Anti-diabetic
action of resveratrol has been extensively studied in animal models and in diabetic humans. In animals with
experimental diabetes, resveratrol has been demonstrated to induce beneﬁcial effects that ameliorate diabetes.
Resveratrol, among others, improves glucose homeostasis, decreases insulin resistance, protects pancreatic β-
cells, improves insulin secretion and ameliorates metabolic disorders. Effects induced by resveratrol are strongly
related to the capability of this compound to increase expression/activity of AMPK and SIRT1 in various tissues
of diabetic subjects. Moreover, anti-oxidant and anti-inﬂammatory effects of resveratrol were shown to be also
involved in its action in diabetic animals.
Preliminary clinical trials show that resveratrol is also effective in type 2 diabetic patients. Resveratrol may,
among others, improve glycemic control and decrease insulin resistance. These results show that resveratrol
holds great potential to treat diabetes and would be useful to support conventional therapy. This article is part
of a Special Issue entitled: Resveratrol: Challenges in translating pre-clincial ﬁndigns to improved patient
outcomes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Diabetesmellitus is a seriousmetabolic disease affecting 382million
people worldwide in 2013. The number of diabetics is estimated to be
dramatically increasing to 592 million in 2035 [1]. According to the
recent classiﬁcation based on the etiology, clinical symptoms and way
of treatment, diabetes is divided into different types. Among them,
type 1 and type 2 diabetes are the most frequent and comprise more
than 90% of all cases. Diabetes is associated with metabolic abnormali-
ties and serious complications. Long-term complications include,
among others, angiopathies, cardiovascular disorders, blindness, renal
failure, neuropathies and increased risk of cancer [2]. Therefore,
management of diabetes should be very effective to prevent diabetes
complications and to improve quality of life of diabetic patients.
Since the discovery of insulin in the early 1920s, there has been
tremendous progress in the treatment of diabetes. Pharmacological
treatment is recently very effective and offers a wide spectrum of anti-
diabetic drugs, such as human insulin, α-glucosidase inhibitors,
dipeptyl peptidase-4 inhibitors, incretin analogues, biguanides, insulin
secretagogues, insulin sensitizers and intestinal lipase inhibitor [3,4].ratol: Challenges in translating
lski).However, despite many efforts, currently used therapies are accompa-
nied by side effects, namely hypoglycemia, gastrointestinal problems,
body weight gain and other [3]. Therefore, new drugs and natural
compounds are continually being tested to better prevent and treat
diabetes [5].
Among various tested compounds, much attention has been paid to
resveratrol because of its pleiotropic activity. Resveratrol (3,5,4’-
trihydroxystilbene) is a natural, biologically active compound present
in different plant species and having beneﬁcial effects in both
animals and humans. Resveratrol is known to induce, among others,
anti-oxidative [6], cardio-protective [6,7], anti-cancer [8,9], anti-
inﬂammatory [10], neuro-protective [11,12] and anti-obesity [13,14]
effects.
In the last decade, anti-diabetic properties of resveratrol have been
extensively studied in various animal models. The obtained results
show that resveratrol is capable of inducing beneﬁcial effects in diabetic
animals and thereby ameliorates diabetes [13,15,16]. Moreover, human
studies have been performed, providing interesting and promising data.
This review summarizes the effects of resveratrol in animal models of
diabetes and in diabetic humans.
2. Resveratrol and type 1 diabetes
Type 1 diabetes accounts for 5-10% of all diabetic cases and results
fromanautoimmune destruction of pancreaticβ-cells. In type 1 diabetic
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sufﬁcient to prevent hyperglycemia. Therefore, insulin deﬁciency and
the resulting frank hyperglycemia are the main hallmarks of type 1 dia-
betes. It is known that elevated blood glucose levels, togetherwith other
detrimental effects, lead over time to various diabetes complications [2].
Maintaining normoglycemia and preservation of pancreatic β-cells are
therefore ofmajor importance in type 1 diabetics. Animal studies clearly
demonstrate that resveratrol decreases blood glucose levels and
protects β-cells.
2.1. Effects of resveratrol on blood glucose levels
It is well established that resveratrol decreases blood glucose levels
in animals with experimental type 1 diabetes. The blood glucose-
lowering effect of resveratrol was found in rats with diabetes induced
by streptozotocin (STZ) alone [17–23] and STZ with nicotinamide
(NA) [24–27]. In animal models, STZ is used to destroy pancreatic
β-cells and thereby induces insulin-deﬁcient diabetes. In β-cells of ani-
mals exposed to STZ, DNA undergoes fragmentation and repairing
mechanisms are activated. The crucial role in DNA repair is ascribed to
poly(ADP-ribose) polymerase-1 (PARP-1). This enzyme catalyses the
synthesis of poly(ADP-ribose) from NAD+ and its action is usually
beneﬁcial to the cell. However, in the case of extensive DNA damage,
an exaggerated action of PARP-1 leads to depletion of intracellular
NAD+ and ATP, and β-cells undergo necrosis. Therefore, animals with
STZ-induced diabetes are characterized by substantial hyperglycemia.
In STZ-NA-induced model, NA, acting via inhibition of PARP-1 and pro-
vision of NAD+, partially protects β-cells against STZ and blood glucose
levels are moderately elevated [28,29]. Numerous studies have demon-
strated that resveratrol is capable of reducing blood glucose levels in
animals with moderate and marked hyperglycemia. It is known that
hyperglycemia in both animals and humanswith type 1 diabetes results
from the increase in hepatic glucose output and from the decrease in
peripheral glucose utilization. Both these processes are regulated by in-
sulin, and the rise in insulin secretion in type 1 diabetic subjects reduces
blood glucose levels. It is well documented that the antihyperglycemic
effect of resveratrol in type 1 diabetic animals results from the increase
in blood insulin levels, the suppression of hepatic glucose output and
the increase in peripheral glucose utilization (see below).
2.2. Effects of resveratrol on blood insulin levels and β-cells
The blood glucose-lowering effect of resveratrol in STZ-induced
[20–22,30] and in STZ-NA-induced [24–27] diabetic rats is associated
with the rise in blood insulin levels. Since pancreatic β-cells are the
only source of insulin, this strongly suggests that resveratrol is capable
of protecting these cells. Rodent studies have conﬁrmed this assump-
tion. The protective action of resveratrol on pancreatic tissue of type 1
diabetic animals has been demonstrated to be partially related to anti-
oxidant activity of this compound. Resveratrol improves anti-oxidant
defense in pancreatic tissue, i.e. increases activities of anti-oxidant
enzymes (superoxide dismutase, catalase, glutathione peroxidase and
glutathione-S-transferase) and protects cells from free radical damage
[26]. Anti-oxidant activity of resveratrol in pancreatic islets is of partic-
ular importance given that anti-oxidant defense of β-cells is very weak,
rendering them susceptible to oxidative stress [31]. Resveratrolwas also
found to reverse degenerative changes in β-cells of STZ-NA-induced
diabetic rats [26] and to prevent STZ-induced β-cell apoptosis. The
decrease in apoptosis is accompanied by blocking of the activity of
caspase-3, is mainly due to the inhibition of PARP cleavage by resvera-
trol and is similar to the effect of nicotinamide [21].
It should be emphasized that resveratrol is effective not only in ani-
mals in which β-cells are damaged by STZ. Resveratrol attenuates also
autoimmune destruction of these cells. This was demonstrated in NOD
mice [32]. In this experimental model, diabetes develops with age in
non-obese animals as a result of autoimmune destruction of β-cells.The diabetic mice are characterized by reduced number of pancreatic
islets, insulitis and many other degenerative changes within islets.
However, resveratrol delays the onset of diabetes in NOD mice and
also ameliorates the severity of the disease. These effects are accompa-
nied by increased total islet number, increased number of insulitis-
free islets and improvement in general islet condition. The protective
action of resveratrol on pancreatic islets is ascribed to the reduction of
pathogenicity of lymphocytes in NOD mice. This is due to resveratrol-
induced downregulation of chemokine receptor 6 (CCR6) expression
on multiple inﬂammatory cell types and the resulting blocking of the
migration of pathogenic cells to the pancreas [32]. Given that type 1
diabetes in humans has autoimmune background, data showing the
effectiveness of resveratrol in mitigating autoimmune destruction of
β-cells are particularly relevant.
2.3. Effects of resveratrol on peripheral glucose utilization and hepatic glu-
cose output
Another important aspect of resveratrol action is its inﬂuence on
skeletal muscle. It was demonstrated that skeletal muscle dysfunction
in animals with type 1 diabetes is mitigated by resveratrol [17,30,33].
Resveratrol ameliorates skeletal muscle pathology via different
mechanisms. It is known that this compound stimulates mitochondrial
biogenesis and improves fatty acid metabolism in muscles of diabetic
animals. Moreover, resveratrol decreases expression of NF-kappaB and
pro-inﬂammatory cytokines (IL-1β and IL-6) in muscle cells [33] and
thereby exerts anti-inﬂammatory effects. Recent research also indicates
that resveratrol decreases oxidative stress in skeletal muscle of animals
with insulin-deﬁcient diabetes [30]. Both inﬂammation and oxidative
stress are known to contribute to myopathy in type 1 diabetics [34].
Importantly, beneﬁcial effects of resveratrol in skeletal muscle of
diabetic animals are associated with increased GLUT4 expression [17]
and with increased intracellular glucose transport [35]. It is thought
that the action of resveratrol on muscle tissue involves both insulin-
dependent and insulin-independent effects [35]. It is also known that
effects of resveratrol in muscle cells of diabetic animals are mediated
via PI3K-Akt pathway [17,30]. In muscle of diabetic rats resveratrol
was demonstrated to increase Akt phosphorylation and this effect was
dependent on PI3K [17,30].
Apart from changes in skeletal muscle, resveratrol was also found to
beneﬁcially affect the liver of diabetic animals. Under physiological
conditions, one of the key functions of the liver is to maintain
normoglycemia. However, in type 1 diabetics, due to insulin deﬁciency,
this function is impaired and hepatic glucose output increases. Animal
studies indicate that the regulatory role of the liver in glucose
homeostasis may be restored by resveratrol. This is associated
with resveratrol-induced changes in the activities of enzymes of carbo-
hydrate metabolism in the liver of type 1 diabetic animals. Resveratrol
decreases activities of key enzymes of gluconeogenesis [25], decreases
the protein level of phosphoenolpyruvate carboxykinase, a rate-
limiting enzyme for gluconeogenesis [17], increases activity of hexoki-
nase and pyruvate kinase and decreases activity of lactate dehydroge-
nase and glucose-6-phosphatase [25]. Moreover, resveratrol increases
glycogen synthase, decreases glycogen phosphorylase and increases
liver glycogen content [25]. These changes lead to the shifting of the
metabolic pathways toward reduced hepatic glucose output. It should
be noted that effects of resveratrol in the liver are accompanied by
increased blood insulin concentrations, suggesting that insulin, at least
in part, is responsible for these changes [25].
Apart frommetabolic changes in the liver, resveratrol is also known
to exert hepatoprotective effects and ameliorates histological abnor-
malities in the liver of type 1 diabetic animals [22,25,36]. Resveratrol-
induced hepatoprotection mainly results from improvement in
anti-oxidant defense mechanisms and anti-inﬂammatory effects.
Resveratrol increases the activity of antioxidant enzymes [22,36] and
also decreases NF-kappaB and IL-1β contents in the liver of diabetic
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sis in the liver of rats with experimental diabetes [33]. Some data also
indicate that resveratrol activates AMPK and increases SIRT1 expression
in the liver of STZ-induced diabetic rats [33,37].
In sum, the anti-diabetic action of resveratrol is recently well
established in animalmodels of insulin-deﬁcient diabetes. It is very like-
ly that the direct inﬂuence of resveratrol on pancreatic β-cells plays a
pivotal role in this action. Resveratrol-induced partial regeneration of
β-cells in diabetic animals results in the increase in blood insulin levels
[20–22,24–27,30]. Then, insulin decreases hepatic glucose output and
increases glucose utilization by insulin-sensitive tissues. Some data
indicate that beneﬁcial effects of resveratrol result also from the direct,
insulin-independent changes in skeletalmuscle and the liver [22,35,36].
This action is associated with the anti-oxidative and anti-inﬂammatory
effects of resveratrol and with beneﬁcial effects of resveratrol on
metabolic disorders. It must be also emphasized that the blood
glucose-lowering effect of resveratrol in hyperglycemic animals
contributes to the protection of β-cells from glucotoxicity and this, in
turn, improves glycemic control.
3. Resveratrol and type 2 diabetes
Type 2 diabetes is ametabolic disorder characterized by impairment
in insulin secretion and action. The resulting hyperglycemia usually
develops gradually and the disease may be undiagnosed for years. The
pathogenesis of type 2 diabetes is complex and involves both genetic
predisposition and environmental factors. It is known that high-
calorie diet and low physical activity increase the risk of type 2 diabetes
[38,39]. Moreover, the incidence of type 2 diabetes increases with age
and is higher in overweight or obese individuals compared with lean
subjects. On the other hand, dietary intervention and increased physical
activitymay delay the onset of type 2 diabetes despite genetic predispo-
sition [40,41]. It is recentlywell established thatmany factors contribute
to the worsening of insulin action and to β-cell failure in type 2
diabetics, including inﬂammation and oxidative stress [42]. However,
insulin resistance and a progressive β-cell failure are still essential prob-
lems in type 2 diabetic patients. In this context, resveratrol was demon-
strated to beneﬁcially affect both insulin action and pancreatic β-cells.
3.1. Effects of resveratrol on insulin resistance
Under physiological conditions, insulin action is preceded by a
sequence of events involving insulin binding with transmembrane
receptor followed by receptor autophosphorylation, phosphorylation
of intracellular insulin receptor substrates and activation of effector
proteins [43]. Insulin resistance, deﬁned as impaired insulin action on
target tissues, i.e. skeletal muscles, the liver and adipose tissue, disturbs
glucose homeostasis and contributes to abnormalities in the whole
organism. Numerous studies have demonstrated that resveratrol
improves insulin action in animals with experimentally induced insulin
resistance. This effect was shown in rats on a high cholesterol-fructose
diet [35], in rats [44,45] and mice [46–50] on a high-fat diet, in rats
fed a high-fat diet and treated with streptozotocin [51] and in fructose
fed rats [52]. Partial reversal of diet-induced insulin resistance by
resveratrol was also demonstrated in a swine model [53]. Resveratrol
is also effective in animals with genetically determined insulin resis-
tance and improves insulin action in obese Zucker rats [54,55], KKAy
mice [56] and db/db mice [57,58]. Moreover, Marchal et al. [59],
studying effects of resveratrol in grey mouse lemur, revealed that this
compound decreases also age related insulin resistance.
Recent research shows that long-term administration of resveratrol
(for 2 years, 80 and 480 mg/day for the ﬁrst and second year, respec-
tively) may improve insulin sensitivity in rhesus monkeys with diet-
induced obesity. Signiﬁcant improvement in insulin sensitivity was
found in these animals at the level of visceral adipose tissue [60].However, other study demonstrated that resveratrol fails to alter indices
of insulin resistance in rhesus monkeys [61].
Animal studies are consistent and indicate that resveratrol improves
insulin action in various models of insulin resistance. Resveratrol-
induced decrease in insulin resistance is known to result from changes
in skeletal muscle, the liver and adipose tissue.
3.1.1. Muscle insulin resistance
In skeletal muscle, stimulation of intracellular glucose transport is
one of the main effects of insulin. Insulin-induced glucose transport
requires translocation of glucose transporter GLUT4 to the plasma
membrane and is preceded by a sequence of events involving various
signaling molecules [43]. It is known that in type 2 diabetes insulin-
induced glucose transport is impaired. Since skeletal muscle accounts
for about 75% of the whole body insulin-induced glucose transport,
this impairmentmarkedly contributes to the rise in blood glucose levels
[43].
Evidence from animal studies indicates that resveratrol promotes
intracellular glucose transport in insulin-resistant rodents. The ﬁrst
animal experiments demonstrated higher glucose uptake by soleus
muscle of rats fed a high cholesterol-fructose diet and receiving resver-
atrol than in animals that were not receiving this compound [35].
Subsequent studies conﬁrmed these results, showing that in rats on a
high-fat diet resveratrol improves insulin-stimulated glucose uptake
by skeletal muscle [44,45]. Resveratrol-induced increase in intracellular
glucose transport in insulin-resistant animals results from two events
related to GLUT4. It is known that resveratrol enhances GLUT4 translo-
cation to the plasma membrane of muscle cells [35,45] and also
increases GLUT4 expression in skeletal muscle of animals with diet-
induced insulin resistance [53] and in db/db mice [62].
Enhanced intracellular glucose transport in insulin-resistant animals
ingesting resveratrol points to the improvement in insulin action. Res-
veratrol ameliorates insulin resistance in skeletal muscle via various
mechanisms, including changes in metabolism and lipid accumulation.
In skeletal muscle of rodents with diet-induced insulin resistance,
resveratrol promotesmitochondrial biogenesis [63] and improvesmito-
chondrial β-oxidation [44]. This leads to increased fatty acid oxidation
and to reduced intramuscular lipid content in animals consuming
resveratrol [44]. The latter effect is of great importance since increased
intramyocellular lipid accumulation impairs insulin action and contrib-
utes to insulin resistance and type 2 diabetes [64]. Moreover, it is
thought thatmusclemitochondrial dysfunction accelerates intramuscu-
lar lipid deposition and impairs insulin action in humans [65]. Therefore,
resveratrol-induced increase in mitochondrial biogenesis with a con-
comitant decrease in intramuscular lipid content seem to be essential
for resveratrol action in muscle tissue.
Beneﬁcial effects of resveratrol in muscle tissue of insulin-resistant
rodents are strongly related to changes in the activities and/or expres-
sion of two intracellular regulators, i.e. SIRT1 and AMPK. SIRT1 (silent
information regulator 1), is NAD+ - dependent histone deacetylase
involved in the regulation of many processes, such as mitochondrial
biogenesis, inﬂammation, intracellular metabolism, stress resistance,
apoptosis, glucose homeostasis and other. It is thought that SIRT1
activity/expression is reduced in type 2 diabetic patients, and this
enzyme is being considered as a target for anti-diabetic drugs [66,67].
Resveratrol is known to activate SIRT1 inmammalian tissues [68]. In an-
imals with diet-induced insulin resistance, resveratrol was also shown
to activate muscle SIRT1 [44]. Activation of this enzyme is associated
with increase in NAD+/NADH ratio [63]. The importance of SIRT1 in
the action of resveratrol was conﬁrmed in mice with genetically
induced insulin resistance, in which resveratrol increases protein level
of SIRT1 in soleus muscle [56].
Apart from SIRT1, AMP-activated protein kinase (AMPK) is another
enzyme involved in resveratrol action. AMPK regulatesmanyphysiolog-
ical processes, including fuel metabolism, mitochondrial function and
biogenesis, insulin secretion and action and other. A close link between
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established [69]. Decreased AMPK activity occurs in animal models
of diet-induced insulin resistance [70] and in insulin resistance
determined genetically [54]. Although the direct link between AMPK
activation and the improvement in insulin resistance in humans is not
proven, it is known that commonly used insulin sensitizing drugs,
metformin and the thiazolidinediones, activate AMPK in different
tissues [69]. Similarly to these drugs, resveratrol also activates AMPK
in insulin-resistant animals. In rodents with diet-induced insulin
resistance, resveratrol restores the phosphorylation of AMPKα [47]
and activates AMPKα in the skeletal muscle [63]. Similar effects were
shown in KKAy mice, in which resveratrol increases protein level of
AMPKα in soleus muscle [56]. Moreover, resveratrol was demonstrated
to be ineffective in insulin-resistant animals with AMPK deﬁciency [63].
These results conﬁrm the relevance of AMPK as a target for resveratrol.
It is also known that resveratrol reduces formation of reactive oxy-
gen species in skeletal muscle of insulin resistant rodents. This effect is
supposed to be alsomediated by AMPK and contributes to the improve-
ment in insulin action [63]. Resveratrol-induced up-regulation of AMPK
in skeletal muscle is associated with deacetylation and activation of
PGC-1α, probably via SIRT1-dependent manner [53,63], and leads to
the increase in mitochondrial biogenesis. It is, however, suggested
that pharmacological activation of AMPK and the resulting stimulation
of mitochondrial biogenesis in skeletal muscle may be insufﬁcient
to improve whole-body energy expenditure and insulin action [71].
These results indicate that, apart from increase in mitochondrial
biogenesis, other effects must be generated by resveratrol in skeletal
muscle.
Resveratrol may also improve insulin signaling in skeletal muscle of
insulin-resistant animals by increased phosphorylation of insulin
receptor [35], increased protein levels of IRS-1 [56] and also enhanced
expression of phosphorylated Akt [53,56] (Fig. 1).3.1.2. Liver insulin resistance
Apart from skeletal muscle, resveratrol is also known to beneﬁcially
affect the liver of insulin-resistant rodents. This compound, among
others, decreases hepatic lipid accumulation and ameliorates steatosis.
These effects are associated with reduced expression of fatty acid syn-
thase (FAS) and acetyl-CoA carboxylase (ACC) and also with increased
expression and activity of carnitine palmitoyl transferase-1 (CPT-1)
[33,49,50,62,72–75].
In parallel with changes in skeletal muscle, resveratrol-induced ef-
fects in the liver are also associated with changes in AMPK/SIRT1
[47,50,56,58,62,76]. It is suggested that effects of resveratrol on FAS,
ACC and CPT-1 are mediated via AMPK/SIRT1 axis [77,78]. In the liver
of animals with diet-induced insulin resistance, resveratrol stimulates
phosphorylation of AMPK [47] and increases protein expression of
SIRT1 [50]. Additionally, resveratrol increases NAD+/NADH ratio in the
liver, which contributes to the activation of SIRT1 [83]. In animalmodels
of insulin resistance determined genetically, resveratrol is also effective
and increases expression andphosphorylation of AMPK and SIRT1 in the
liver [54,56,58,62,76].
Importantly, resveratrol improves also insulin signaling in the liver
of insulin-resistant animals and increases phosphorylation of several
signaling proteins, including IRS-1, Akt and PI3K [79]. Moreover,
resveratrol was found to increase the activity of glutathione
peroxidase decreasing oxidative damage of the liver [76] and to
reduce expression of pro-inﬂammatory cytokines in liver tissue [50,
74]. Resveratrol is also capable of reducing macrophage inﬁltration in
the liver of animals on a high-fat diet [49] (Fig. 1).Fig. 1. Direct and indirect effects thereby resveratrol improves insulin action in skeletal muscle
also demonstrated in type 2 diabetic humans. RSV – resveratrol, ROS – reactive oxygen species, I
PGC1α – peroxisome proliferator-activated receptor γ coactivator-α, ACC – acetyl-CoA carboxy
peroxidase.3.1.3. Adipose insulin resistance
It is known that resveratrol affects also adipose tissue in type 2
diabetic subjects. Adipose tissue dysfunction plays an important role
in the pathogenesis of type 2 diabetes. Under physiological conditions,
adipocytes store excess of energy in the form of triglycerides or release
glycerol and fatty acids, depending on the actual demand of the organ-
ism. However, increased accumulation of fat tissue leads to overweight
or obesity. Adipose tissue-related impairment in insulin action results
from various effects. It is known that increased release of free fatty
acids plays an important role in the development of insulin resistance
[80,81]. Moreover, adipose tissue secretes multiple adipokines which
may also impair insulin action leading to insulin resistance [82]. In the
last years, there is growing evidence that adipose tissue inﬂammation
markedly contributes to insulin resistance and type 2 diabetes in
humans [82–84]. In this context, anti-inﬂammatory effects of resvera-
trol in both animals and humans are of particular importance [10,85].
Numerous studies show that resveratrol is capable of reducing inﬂam-
matory processes in adipose tissue of insulin-resistant animals. This
was found in genetically obese Zucker rats [81] as well as in rodents
[46,49,54] and nonhumanprimates [60]with diet-induced insulin resis-
tance. Resveratrol attenuates high-fat diet-induced up-regulation of
pro-inﬂammatory cytokines and their signaling molecules in adipose
tissue and thereby reduces inﬂammation [46]. Beneﬁcial effects of this
compound are also associated with reduced macrophage inﬁltration in
adipose tissue of obese rats [75] and mice on a high-fat diet [49]. More-
over, resveratrol induces white adipose tissue mitochondrial biogenesis
and improves tissue metabolism in insulin-resistant rodents [55,63,86].
The latter effect is associated, among others, with reduced activity of
lipogenic enzymes (glucose-6-P-dehydrogenase, acetyl-CoA carboxyl-
ase and lipoprotein lipase) [75]. Anti-diabetic action of resveratrol
may be also related to anti-obesity effects of this compound [13,14]. It
is well known that increased adiposity impairs insulin action and in-
creases the risk of type 2 diabetes in humans [2,40]. Some studies
show that resveratrol is capable of reducing adipose tissueweight in an-
imals with insulin resistance [46,54,75,87]. Anti-obesity effect of resver-
atrol is associated not only with improvement in adipose tissue
metabolism, but also with reduced adipogenesis in animals on a high-
fat diet. The latter effect is due to down-regulation of key adipogenic
genes [46]. However, it was also shown that resveratrol may improve
insulin action without detectable changes in adiposity [55] or decrease
in body weight [49,56]. This suggests that decrease in body weight is
not a prerequisite to improve insulin action by resveratrol.
Similarly to other tissues, effects of resveratrol on adipose tissue are
accompanied by changes in AMPK and SIRT1. It is known that resvera-
trol increases AMPKα phosphorylation/activity in white adipose tissue
of insulin-resistant mice [63,87] and obese Zucker rats [54]. Moreover,
in rhesus monkeys and mice with diet-induced insulin resistance,
resveratrol was demonstrated to improve insulin sensitivity in
adipose tissue and these effects are associated with increased SIRT1
expression [60,87] (Fig. 1).
It is well established that resveratrol is capable of attenuating insulin
resistance in various animal models. This is of importance and points to
the potential of resveratrol to treating different diseases associatedwith
impaired insulin action, including type 2 diabetes. However, in the light
of the possible use of resveratrol in type 2 diabetic patients, human
studies are necessary to evaluate its therapeutic value.
Human studies addressing the anti-diabetic action of resveratrol are
still limited, however, available data indicate that this compound is ca-
pable of decreasing insulin resistance. Brasnyό et al. [88] demonstrated
for the ﬁrst time that resveratrol administered for 4 weeks to, liver and adipose tissue of animals with experimental type 2 diabetes. Some effects were
RS1 – insulin receptor substrate 1, PI3K - phosphoinositide 3-kinase, Akt – protein kinase B,
lase, FAS – fatty acid synthase, CPT-1 – carnitine palmitoyltransferase 1, GPx – glutathione
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quent studies conﬁrmed the efﬁcacy of resveratrol in insulin-resistant
humans. Resveratrol administered for 4 weeks to obese type 2 diabetic
patients was found to decrease insulin resistance [89]. Similar results
were observed in overweight type 2 diabetic patients receiving resver-
atrol for 45 days [90]. In each of these studies, HOMA-IR index was cal-
culated to determine insulin resistance and its values were signiﬁcantly
improved by resveratrol. It was also found that resveratrol administered
to type 2 diabetic patients for 3 months slightly reduced fasting blood
glucose levels and hemoglobin A1c levels, showing long-term improve-
ment in glycemia [91]. Moreover, resveratrol administered for 4 weeks
to humans with age-related impairment in glucose tolerance was dem-
onstrated to reduce postprandial blood glucose and insulin levels and
slightly improved insulin sensitivity (determined by Matsuda index)
[92]. A slight improvement in insulin sensitivity was also shown in pa-
tients with metabolic syndrome ingesting resveratrol for 3 months
[93]. However, some studies demonstrated lack of effect. Resveratrol
administered for twoweeks to obesemen did not signiﬁcantly affect in-
sulin resistance [94]. Moreover, in obese humans with type 2 diabetes,
resveratrol was given for 4 weeks and failed to change blood glucose
and blood insulin levels and did not affect insulin resistance [72]. Simi-
larly, in overweight type 2 diabetic patients, resveratrol administered
for 60 days failed to ameliorate insulin resistance [95]. Lack of effects
of resveratrol administered for 8 weeks on insulin resistance and in-
ﬂammation was also found in overweight or obese man with nonalco-
holic fatty liver disease [96]. It was also demonstrated that resveratrol
is ineffective in healthy people and does not induce any signiﬁcant
changes in insulin sensitivity and inﬂammatory status [97,98] (Table 1).
The discrepancies among studies in the efﬁcacy of resveratrol in in-
sulin resistant humansmay be explained by differences in experimentalTable 1
Effects of resveratrol in humans.
Effect Resveratrol dose/
time of treatment
Insulin resistance ↓ 5 mg twice a day
4 weeks
Insulin resistance ↓
Blood glucose levels ↓
HOMA-β ↓
Systolic blood pressure ↓
500 mg twice a day
45 days
Insulin resistance−
Blood glucose levels ↓
Diabetic ulcer size ↓
50 mg twice a day
60 days
Blood glucose levels ↓
Systolic blood pressure ↓
250 mg per day
3 months
Insulin resistance ↓
Blood glucose levels ↓
Plasma inﬂammation markers ↓
Systolic blood pressure ↓
150 mg per day
30 days
Insulin resistance−
Blood glucose levels−
Intestinal and hepatic lipoprotein production ↓
First week 1 g per day second
week 2 g per day
two weeks
Postprandial glucagon responses ↓ 150 mg per day
30 days
Insulin resistance ↓ 1, 1.5, 2 g per day
4 weeks
Insulin resistance−
Plasma inﬂammation markers−
Systolic blood pressure−
500 mg 3 times a day
4 weeks
Insulin resistance ↓
Systolic blood pressure−
500 mg 3 times a day
90 days
Insulin sensitivity –
Plasma inﬂammation markers−
Systolic blood pressure−
75 mg per day
12 weeks
Insulin resistance− 3 g per day
8 weeks
Metabolic and inﬂammatory
status in skeletal muscle−
250 mg per day
8 weeks
↓, Decrease;−,unchanged.conditions, such as dose of resveratrol and time of treatment, age and
body weight of patients, duration and severity of diabetes, diabetes
complications, nutrition and other.
Compared with animal studies, human data are less conclusive,
however, preliminary clinical trials indicate that resveratrol may de-
crease insulin resistance in type 2 diabetic patients. Beneﬁcial effects
of resveratrol in humans with type 2 diabetes appear to be linked to
changes in SIRT1 and AMPK [89,99]. Resveratrol administered to obese
insulin-resistant humans was found to activate AMPK and increase
PGC-1α and SIRT1protein levels in skeletalmuscle [89]. Similar changes
were observed in skeletal muscle of patients with type 2 diabetes, in
which resveratrol increased SIRT1 expression as well as p-AMPK to
AMPK expression ratio [99]. In type 2 diabetic humans, resveratrol
was also found to induce Akt phosphorylation [88].3.2. Effects of resveratrol on blood insulin levels and β-cells
Under physiological conditions, insulin secretion from pancreatic
β-cells is tightly regulated and is inﬂuenced by many factors, including
nutrients, nervous system, some hormones and other [100,101]. In type
2 diabetic humans, insulin resistance leads to the increased demand of
insulin, β-cells secrete more hormone and blood insulin levels are ini-
tially elevated. However, prolonged overstimulation of these cells and
exaggerated insulin secretion, together with other detrimental factors,
contribute to the progressiveβ-cell failure and, over time, insulin supply
becomes insufﬁcient. It is known that the β-cell failure in type 2 diabetic
patients is generated by glucotoxicity, lipotoxicity, oxidative stress,
inﬂammation, amyloid formation, endoplasmic reticulum stress and
other factors [42].Subjects References
Type 2 diabetic patients [88]
Type 2 diabetic patients [90]
Type 2 diabetic patients [95]
Type 2 diabetic patients [91]
Obese men [89]
Obese men [94]
Obese men [110]
Older adults [92]
Obese men [72]
Patients with metabolic syndrome [93]
Nonobese women with normal glucose tolerance [98]
Overweight or obese men with nonalcoholic fatty
liver disease and IR
[96]
Healthy aged men [97]
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changes in islet β-cell mass. In type 2 diabetic patients, β-cell mass
is usually reduced [42]. Abnormalities in β-cell structure and function
which develop in type 2 diabetes are extensively studied using
various animal models. In animal models of type 2 diabetes, blood
insulin levels and β-cell mass may be increased or decreased,
depending on the kind of the model [102,103]. Over the past few
years, effects of resveratrol were studied using rodents in which
β-cell mass and blood insulin levels were increased or decreased. In-
terestingly, the obtained data clearly show that resveratrol is effective
in both cases.
In animals with insulin resistance and hyperinsulinemia, resveratrol
was found to reduce blood insulin concentrations. This effect was dem-
onstrated in rodents with diet-induced hyperinsulinemia [47–50,52]
and in the genetically obese Zucker rats [54]. On the other hand, in ro-
dent models of type 2 diabetes with decreased β-cell mass and
hypoinsulinemia, resveratrol appears to increase blood insulin levels,
as shown in db/db mice [57,62].
Long-term studies with resveratrol reveal the effectiveness of this
compound in nonhuman primates with abnormalities in islet structure
and function. In rhesus monkeys, diet-induced increase in theα-cell/β-
cell ratio in pancreatic islets was signiﬁcantly improved by resveratrol
administered to these animals for 2 years [61].
The mechanism underlying resveratrol action is complex and in-
volves different effects. It is very likely that one of the most important
is attenuation of insulin resistance in diabetic animals and humans.
The improvement in insulin action leads to decrease in blood glucose
levels and thereby prevents deleterious effects of hyperglycemia on
β-cells, known as glucotoxicity [104]. Moreover, resveratrol was also
demonstrated to reduce blood lipid levels in diabetic subjects and there-
bydecreases so-called lipotoxicity. The attenuation of both glucotoxicity
and lipotoxicity is well known to restrain β-cell failure in diabetes [104,
105]. Another advantage of resveratrol-induced decrease in insulin re-
sistance is reduced demand of insulin. As a result, less insulin is secreted
from β-cells and thereby β-cell failure is also reduced.
Protective action of resveratrol on pancreaticβ-cells is also related to
its well-documented anti-oxidative capacity. Resveratrol was demon-
strated to reduce oxidative damage in β-cells of type 2 diabetic animalsFig. 2. Direct and indirect effects thereby resveratrol improves insulin secretion from pancreati
ygen species, UCP2 – uncoupling protein 2.[48,57,62,106]. This is very important since insulin-secreting cells are
particularly susceptible to the oxidative damage [31]. Moreover, oxida-
tive stress is increased in diabetes and contributes to the progressive
β-cell failure.
It is known that that resveratrol exerts also anti-inﬂammatory
action, decreases levels of inﬂammatory markers [26] and thereby
protects pancreatic β-cells of type 2 diabetic animals. Recently, there
is growing evidence for the important role of inﬂammation in the pro-
gressive β-cell dysfunction in type 2 diabetic humans. It is thought
that in type 2 diabetes inﬂammatory response is initiated to promote
β-cell repair and regeneration. However, over time, chronic inﬂamma-
tion develops leading to the functional impairment of the insulin-
secreting cells [83].
Resveratrol was also demonstrated to reduce pancreatic triglyceride
content in animals on a high-fat diet [48]. It was also found that in mice
on a high-fat diet with increased β-cell mass, resveratrol returns β-cell
mass to the values observed in control animals. This is related to
beneﬁcial effects on expression of apoptosis-related factors in pancreat-
ic islets (bcl-2 and bax) [48]. Moreover, resveratrol increases SIRT1
expression and decreases uncoupling protein-2 (UCP2) expression in
islet cells [48]. UCP-2 is a mitochondrial membrane protein which un-
couples oxygen consumption from the production of ATP and thereby
negatively modulates insulin secretion [107]. Increased UCP-2 expres-
sion in β-cells is proposed to protect these cells against reactive oxygen
species. On the other hand, up-regulation of UCP-2 in the insulin-
secreting cells, observed, among others, in some animal models of
diet-induced β-cell dysfunction [48], is a marker of stress condi-
tions [108,109]. In this context, decrease of UCP-2 expression caused
by resveratrol is beneﬁcial and points to the functional improvement
of β-cells.
In db/db mice, an animal model of type 2 diabetes with decreased
β-cell mass, resveratrol was shown to improve islet structure and func-
tion, reduces oxidative stress, restores islet architecture, decreases islet
destruction,markedly reduces islet ﬁbrosis and attenuates other degen-
erative changes. Moreover, resveratrol partially prevents β-cell failure
and increases β-cell mass [57,62] (Fig. 2).
Importantly, beneﬁcial effects of resveratrol on β-cells were also
shown in type 2 diabetic patients. Recent studies demonstrated thatc islets of animals with experimental type 2 diabetes. RSV – resveratrol, ROS – reactive ox-
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hyperinsulinemia. This effect was accompanied by a concomitant de-
crease in homeostasis model of assessment for β-cell function
(HOMA-β) [90]. However, other studies demonstrated that, although
resveratrol induced some beneﬁcial effects in type 2 diabetic patients,
blood insulin levels and HOMA-β were unchanged by this compound
[88]. These results indicate that resveratrol is capable of improving
β-cell function not only in rodents and nonhuman primates, but also
in humans with type 2 diabetes.
4. Conclusions and additional remarks
Resveratrol is known to have numerous health-promoting effects in
both animals and humans. It is recently well established that this com-
pound induces also beneﬁcial effects in animals with experimental
insulin-deﬁcient diabetes, including antihyperglycemic action and
protection of pancreatic β-cells and has a potential to support the
conventional treatment of type 1 diabetes. However, human studies re-
main to be performed to verify the effectiveness of resveratrol in type 1
diabetics.
A large body of evidence indicates that resveratrol exerts also
anti-diabetic action in animal models of type 2 diabetes. It is known
that resveratrol improves pancreatic islet structure and function and
decreases insulin resistance in diabetic animals. Effects of resveratrol
are strongly linked to changes in expression and activity of AMPK and
SIRT1 in different tissues of diabetic animals. Resveratrol is also
known to have anti-oxidant and anti-inﬂammatory properties and
thereby ameliorates diabetes. It must be emphasized that resveratrol
is capable of inducing a wide variety of effects in different tissues and
this pleiotropic action leads to the therapeutic effect in the whole
organism.
Preliminary human studies addressing the effects of resveratrol in
type 2 diabetes conﬁrm the effectiveness of this compound. It is of
particular importance that resveratrol improves glycemic control and
decreases insulin resistance. Apart from these changes, ingestion of
resveratrol may also have other health beneﬁts in type 2 diabetic
humans [89,90,94,110], including reduced diabetes complications [95]
(Table 1).
The available data indicate that effective doses of resveratrol in
insulin-resistant humans are very diverse (Table 1). In this context, it
is important to note that the mechanisms of resveratrol action may dif-
fer depending on its dose. Treatment with lower doses of resveratrol
may activate SIRT1, whereas higher doses activate AMPK in a SIRT1-
independent manner [111]. Moreover, in some cases resveratrol may
be less effective at higher doses compared with effects induced by this
compound at lover doses [75,112]. It was demonstrated that doses of
resveratrol lower than 0.5 g per personmay be sufﬁcient to improve in-
sulin action, decrease blood glucose levels and to induce other effects.
Studies on the toxicity of resveratrol in humans show that this com-
pound is well tolerated and doses up to 0.5 g per day for long periods
may induce only moderate and reversible side effects [113].
Human studies, although provide promising results, are not fully
consistent. The discrepanciesmay result fromdifferences in experimen-
tal conditions. Moreover, two major limitations in the human clinical
trials are sample size and the short duration of the trials. However, the
current state of knowledge encourages the further research which
would result in common use of resveratrol in diabetic humans.
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